Virtual Clinical Trials of BMP4 Differentiation Therapy: Digital Twins to Aid Glioblastoma Trial Design

BioXriv
MathOnco
Preprint
MathBio
Authors
Affiliations

Nicholas Harbour

Center for Mathematical Medicine and Biology, University of Nottingham, UK

Lee Curtin

Mathematical Neuro-Oncology lab, Mayo Clinic Phoenix, AZ, USA

Matthew E Hubbard

School of Mathematical Sciences, University of Nottingham, UK

Pamela R Jackson

Mathematical Neuro-Oncology lab, Mayo Clinic Phoenix, AZ, USA

Vinitha Rani

Department of Neurosurgery, Mayo Clinic Jacksonville, FL, USA

Rajappa S Kenchappa

Department of Neurosurgery, Mayo Clinic Jacksonville, FL, USA

Virginea Araujo Farias

Department of Neurosurgery, Mayo Clinic Jacksonville, FL, USA

Anna Carrano

Department of Neurosurgery, Mayo Clinic Jacksonville, FL, USA

Alfredo Quinones-Hinojosa

Department of Neurosurgery, Mayo Clinic Jacksonville, FL, USA

Markus Owen

Center for Mathematical Medicine and Biology, University of Nottingham, UK

Kristin R Swanson

Mathematical Neuro-Oncology lab, Mayo Clinic Phoenix, AZ, USA

Published

August 23, 2024

Doi

Abstract

We leverage an integrative mathematical modeling framework to translate the impact of preclinical findings in virtual clinical trials. We develop a virtual clinical trial pipeline to face the real-world problem of numerous of actual early phase clinical trials that have failed for glioma/glioblastoma, the most common primary brain tumor. Even with the most promising preclinical data, designing clinical trials is fraught with challenges, including controlling for the many parameters used to inform patient selection criteria. Here, we introduce a virtual trial pipeline that allows us to consider the variability from some of these criteria that can be used for future trials of novel therapies. As an example, we apply this to the proposed delivery of BMP4 to stem cell niches present in glioblastoma, the most aggressive glioma, known for its inter- and intra-patient heterogeneity. The proposed approach of BMP4 treatment, delivered through adipose-derived mesenchymal stem cells, aims to promote cellular differentiation away from the treatment-resistance stem cell niches towards a more treatment-vulnerable state. This pipeline will help us narrow down strategies for future trials, optimize timing of treatments relative to key standard-of-care treatments, and predict synergy amongst the developed treatments.

Citation

BibTeX citation:
@article{harbour2024,
  author = {Harbour, Nicholas and Curtin, Lee and E Hubbard, Matthew and
    R Jackson, Pamela and Rani, Vinitha and S Kenchappa, Rajappa and
    Araujo Farias, Virginea and Carrano, Anna and Quinones-Hinojosa,
    Alfredo and Owen, Markus and R Swanson, Kristin},
  title = {Virtual {Clinical} {Trials} of {BMP4} {Differentiation}
    {Therapy:} {Digital} {Twins} to {Aid} {Glioblastoma} {Trial}
    {Design}},
  journal = {bioRxiv},
  date = {2024-08-23},
  doi = {10.1101/2024.08.22.609156},
  langid = {en}
}
For attribution, please cite this work as:
Harbour, Nicholas, Lee Curtin, Matthew E Hubbard, Pamela R Jackson, Vinitha Rani, Rajappa S Kenchappa, Virginea Araujo Farias, et al. 2024. “Virtual Clinical Trials of BMP4 Differentiation Therapy: Digital Twins to Aid Glioblastoma Trial Design.” bioRxiv, August. https://doi.org/10.1101/2024.08.22.609156.